Oligomeric ACE2 Constructs for SARS-CoV-2 Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating coronavirus infections, particularly SARS-CoV-2, face challenges in producing high-quality, intact viral fusion proteins and effectively binding to the ACE2 cellular receptor, limiting diagnostic and therapeutic efficacy.
Innovation Solution
Development of polypeptide monomers and oligomeric complexes comprising an ACE2 ectodomain with an oligomerization domain, such as a foldon trimerization tag, to enhance stability and binding affinity to the S protein, allowing for improved diagnostic detection and therapeutic intervention.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monomeric ACE2 is used, then production is simpler, but binding affinity to S protein is insufficient
Solution Approach 1:
The patent merges multiple ACE2 monomers into oligomeric complexes (dimers, trimers, tetramers) to enhance binding affinity. The oligomerization domain enables multiple ACE2 units to associate and bind to multiple S protein units simultaneously, creating higher avidity while maintaining individual monomer functionality.
Solution Approach 2:
The ACE2 protein is segmented into functional domains: the ectodomain for S protein binding, the transmembrane region for membrane anchoring, and the cytoplasmic tail for intracellular signaling. The oligomerization domain is added as a separate functional module that enables multimerization without disrupting the ectodomain's binding capability.
2Measurement precision
If intact viral fusion proteins are produced, then diagnostic accuracy improves, but production quality remains challenging
Solution Approach 1:
The patent extracts and isolates the ACE2 ectodomain as a soluble, stable protein component that can be produced independently of the complete viral fusion protein. This extracted ACE2 domain maintains binding functionality while being easier to produce in high quality and quantity through recombinant expression systems.
Solution Approach 2:
The oligomerization domain acts as an intermediary element that facilitates the assembly of ACE2 monomers into stable oligomeric complexes. This intermediary domain enables controlled self-assembly without requiring complex purification processes, improving manufacturing precision while maintaining diagnostic accuracy.
3Reliability
If ACE2 binds S protein, then viral entry is inhibited, but dissociation occurs reducing therapeutic duration
Solution Approach 1:
Multiple ACE2 monomers are merged into oligomeric complexes that bind to multiple S protein units on the viral surface simultaneously. This multivalent binding creates a more stable complex that resists dissociation, extending the therapeutic duration by maintaining continuous inhibition of viral entry.
Solution Approach 2:
The patent introduces stabilizing mutations in the ACE2 ectodomain that alter the binding parameters to increase affinity and decrease off-rate. These parameter changes in the protein structure enable more stable and prolonged binding to the S protein, extending therapeutic action.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ACE2-based constructs demonstrate increased stability and binding avidity, enabling effective detection and treatment of SARS-CoV-2 infections by slowing dissociation and enhancing interaction with the S protein, thereby improving diagnostic sensitivity and therapeutic potency.
Implementation Method 1
the oligomerization domain provides for the trimerization of the polypeptide monomers
Implementation Method 2
ACE2 binds the S proteins of SARS-CoV and SARS-CoV-2
Data Source
AI summary
Provided herein, in some aspects, are polypeptide monomers comprising an angiotensin-converting enzyme 2 (ACE2) ectodomain and an oligomerization domain. Also provided herein are oligomeric complexes comprising ACE2 monomers. Methods of using such to monomers and oligomeric complexes for the diagnosis, prevention, and treatment of viral infections such as the coronavirus are also provided.